GSK PLC-SPON ADR (GSK) Stock Fundamental Analysis

NYSE:GSK • US37733W2044

58.325 USD
-0.16 (-0.28%)
Last: Feb 12, 2026, 10:28 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

Overall GSK gets a fundamental rating of 6 out of 10. We evaluated GSK against 191 industry peers in the Pharmaceuticals industry. GSK has an excellent profitability rating, but there are some minor concerns on its financial health. GSK may be a bit undervalued, certainly considering the very reasonable score on growth


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • GSK had positive earnings in the past year.
  • In the past year GSK had a positive cash flow from operations.
  • In the past 5 years GSK has always been profitable.
  • Each year in the past 5 years GSK had a positive operating cash flow.
GSK Yearly Net Income VS EBIT VS OCF VS FCFGSK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 9.35%, GSK belongs to the top of the industry, outperforming 91.10% of the companies in the same industry.
  • With an excellent Return On Equity value of 34.90%, GSK belongs to the best of the industry, outperforming 95.29% of the companies in the same industry.
  • GSK has a Return On Invested Capital of 19.19%. This is amongst the best in the industry. GSK outperforms 95.81% of its industry peers.
Industry RankSector Rank
ROA 9.35%
ROE 34.9%
ROIC 19.19%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GSK Yearly ROA, ROE, ROICGSK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K -2K

1.3 Margins

  • GSK has a better Profit Margin (17.50%) than 89.53% of its industry peers.
  • In the last couple of years the Profit Margin of GSK has declined.
  • GSK's Operating Margin of 27.47% is amongst the best of the industry. GSK outperforms 93.19% of its industry peers.
  • GSK's Operating Margin has improved in the last couple of years.
  • The Gross Margin of GSK (72.67%) is better than 80.10% of its industry peers.
  • In the last couple of years the Gross Margin of GSK has remained more or less at the same level.
Industry RankSector Rank
OM 27.47%
PM (TTM) 17.5%
GM 72.67%
OM growth 3Y-1.36%
OM growth 5Y2.22%
PM growth 3Y-29.99%
PM growth 5Y-5.81%
GM growth 3Y0.72%
GM growth 5Y0.77%
GSK Yearly Profit, Operating, Gross MarginsGSK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so GSK is creating value.
  • There is no outstanding debt for GSK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GSK Yearly Shares OutstandingGSK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B
GSK Yearly Total Debt VS Total AssetsGSK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B

2.2 Solvency

  • An Altman-Z score of 2.36 indicates that GSK is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • GSK has a better Altman-Z score (2.36) than 63.35% of its industry peers.
  • GSK has a debt to FCF ratio of 3.73. This is a good value and a sign of high solvency as GSK would need 3.73 years to pay back of all of its debts.
  • GSK's Debt to FCF ratio of 3.73 is amongst the best of the industry. GSK outperforms 87.43% of its industry peers.
  • A Debt/Equity ratio of 0.90 indicates that GSK is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.90, GSK is doing worse than 71.73% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF 3.73
Altman-Z 2.36
ROIC/WACC2.06
WACC9.33%
GSK Yearly LT Debt VS Equity VS FCFGSK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B 15B 20B

2.3 Liquidity

  • A Current Ratio of 0.82 indicates that GSK may have some problems paying its short term obligations.
  • GSK has a worse Current ratio (0.82) than 87.96% of its industry peers.
  • A Quick Ratio of 0.54 indicates that GSK may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.54, GSK is not doing good in the industry: 88.48% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.82
Quick Ratio 0.54
GSK Yearly Current Assets VS Current LiabilitesGSK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 7.84% over the past year.
  • The Earnings Per Share has been growing slightly by 3.55% on average over the past years.
  • Looking at the last year, GSK shows a small growth in Revenue. The Revenue has grown by 4.11% in the last year.
  • The Revenue has been growing slightly by 6.05% on average over the past years.
EPS 1Y (TTM)7.84%
EPS 3Y5.13%
EPS 5Y3.55%
EPS Q2Q%9.91%
Revenue 1Y (TTM)4.11%
Revenue growth 3Y3.66%
Revenue growth 5Y6.05%
Sales Q2Q%6.17%

3.2 Future

  • The Earnings Per Share is expected to grow by 5.00% on average over the next years.
  • Based on estimates for the next years, GSK will show a small growth in Revenue. The Revenue will grow by 2.96% on average per year.
EPS Next Y8.81%
EPS Next 2Y8.7%
EPS Next 3Y9.89%
EPS Next 5Y5%
Revenue Next Year5.1%
Revenue Next 2Y4.85%
Revenue Next 3Y4.35%
Revenue Next 5Y2.96%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
GSK Yearly Revenue VS EstimatesGSK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B
GSK Yearly EPS VS EstimatesGSK Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 12.18, the valuation of GSK can be described as correct.
  • 88.48% of the companies in the same industry are more expensive than GSK, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of GSK to the average of the S&P500 Index (28.18), we can say GSK is valued rather cheaply.
  • Based on the Price/Forward Earnings ratio of 11.19, the valuation of GSK can be described as reasonable.
  • 87.43% of the companies in the same industry are more expensive than GSK, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 28.01. GSK is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 12.18
Fwd PE 11.19
GSK Price Earnings VS Forward Price EarningsGSK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, GSK is valued cheaply inside the industry as 91.10% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, GSK is valued cheaply inside the industry as 87.43% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 17.99
EV/EBITDA 7.85
GSK Per share dataGSK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

  • GSK's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The excellent profitability rating of GSK may justify a higher PE ratio.
PEG (NY)1.38
PEG (5Y)3.43
EPS Next 2Y8.7%
EPS Next 3Y9.89%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. Dividend

5.1 Amount

  • GSK has a Yearly Dividend Yield of 3.26%. Purely for dividend investing, there may be better candidates out there.
  • Compared to an average industry Dividend Yield of 0.93, GSK pays a better dividend. On top of this GSK pays more dividend than 94.76% of the companies listed in the same industry.
  • GSK's Dividend Yield is rather good when compared to the S&P500 average which is at 1.80.
Industry RankSector Rank
Dividend Yield 3.26%

5.2 History

  • The dividend of GSK decreases each year by -9.84%.
  • GSK has been paying a dividend for at least 10 years, so it has a reliable track record.
  • The dividend of GSK decreased recently.
Dividend Growth(5Y)-9.84%
Div Incr Years1
Div Non Decr Years1
GSK Yearly Dividends per shareGSK Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.5 1 1.5 2

5.3 Sustainability

  • 44.86% of the earnings are spent on dividend by GSK. This is a bit on the high side, but may be sustainable.
DP44.86%
EPS Next 2Y8.7%
EPS Next 3Y9.89%
GSK Yearly Income VS Free CF VS DividendGSK Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B
GSK Dividend Payout.GSK Dividend Payout, showing the Payout Ratio.GSK Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

GSK PLC-SPON ADR

NYSE:GSK (2/12/2026, 10:28:07 AM)

58.325

-0.16 (-0.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-04
Earnings (Next)04-29
Inst Owners43.55%
Inst Owner Change204.24%
Ins Owners0.1%
Ins Owner ChangeN/A
Market Cap117.04B
Revenue(TTM)32.67B
Net Income(TTM)5.72B
Analysts70
Price Target51.62 (-11.5%)
Short Float %0.89%
Short Ratio4.14
Dividend
Industry RankSector Rank
Dividend Yield 3.26%
Yearly Dividend1.66
Dividend Growth(5Y)-9.84%
DP44.86%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.74%
Min EPS beat(2)8.69%
Max EPS beat(2)12.8%
EPS beat(4)4
Avg EPS beat(4)9.75%
Min EPS beat(4)7.67%
Max EPS beat(4)12.8%
EPS beat(8)8
Avg EPS beat(8)11.8%
EPS beat(12)11
Avg EPS beat(12)9.51%
EPS beat(16)15
Avg EPS beat(16)10.21%
Revenue beat(2)0
Avg Revenue beat(2)-0.76%
Min Revenue beat(2)-1.24%
Max Revenue beat(2)-0.28%
Revenue beat(4)0
Avg Revenue beat(4)-0.79%
Min Revenue beat(4)-1.6%
Max Revenue beat(4)-0.04%
Revenue beat(8)3
Avg Revenue beat(8)-0.16%
Revenue beat(12)7
Avg Revenue beat(12)1.25%
Revenue beat(16)9
Avg Revenue beat(16)-0.18%
PT rev (1m)4.11%
PT rev (3m)14.72%
EPS NQ rev (1m)-4.83%
EPS NQ rev (3m)-3.66%
EPS NY rev (1m)-0.44%
EPS NY rev (3m)-0.46%
Revenue NQ rev (1m)-0.87%
Revenue NQ rev (3m)-0.49%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.47%
Valuation
Industry RankSector Rank
PE 12.18
Fwd PE 11.19
P/S 2.62
P/FCF 17.99
P/OCF 11.05
P/B 5.22
P/tB N/A
EV/EBITDA 7.85
EPS(TTM)4.79
EY8.21%
EPS(NY)5.21
Fwd EY8.93%
FCF(TTM)3.24
FCFY5.56%
OCF(TTM)5.28
OCFY9.05%
SpS22.27
BVpS11.16
TBVpS-5.04
PEG (NY)1.38
PEG (5Y)3.43
Graham Number34.69
Profitability
Industry RankSector Rank
ROA 9.35%
ROE 34.9%
ROCE 22.59%
ROIC 19.19%
ROICexc 20.98%
ROICexgc 60.71%
OM 27.47%
PM (TTM) 17.5%
GM 72.67%
FCFM 14.56%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-1.36%
OM growth 5Y2.22%
PM growth 3Y-29.99%
PM growth 5Y-5.81%
GM growth 3Y0.72%
GM growth 5Y0.77%
F-Score9
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF 3.73
Debt/EBITDA 1.15
Cap/Depr 79.01%
Cap/Sales 9.14%
Interest Coverage 13.22
Cash Conversion 60.7%
Profit Quality 83.21%
Current Ratio 0.82
Quick Ratio 0.54
Altman-Z 2.36
F-Score9
WACC9.33%
ROIC/WACC2.06
Cap/Depr(3y)99.36%
Cap/Depr(5y)105.31%
Cap/Sales(3y)8.79%
Cap/Sales(5y)9.19%
Profit Quality(3y)103.9%
Profit Quality(5y)92.12%
High Growth Momentum
Growth
EPS 1Y (TTM)7.84%
EPS 3Y5.13%
EPS 5Y3.55%
EPS Q2Q%9.91%
EPS Next Y8.81%
EPS Next 2Y8.7%
EPS Next 3Y9.89%
EPS Next 5Y5%
Revenue 1Y (TTM)4.11%
Revenue growth 3Y3.66%
Revenue growth 5Y6.05%
Sales Q2Q%6.17%
Revenue Next Year5.1%
Revenue Next 2Y4.85%
Revenue Next 3Y4.35%
Revenue Next 5Y2.96%
EBIT growth 1Y15.03%
EBIT growth 3Y2.25%
EBIT growth 5Y8.41%
EBIT Next Year30.24%
EBIT Next 3Y13.85%
EBIT Next 5Y7.82%
FCF growth 1Y33.15%
FCF growth 3Y-2.59%
FCF growth 5Y-5.17%
OCF growth 1Y18.11%
OCF growth 3Y1.5%
OCF growth 5Y-1.72%

GSK PLC-SPON ADR / GSK FAQ

Can you provide the ChartMill fundamental rating for GSK PLC-SPON ADR?

ChartMill assigns a fundamental rating of 6 / 10 to GSK.


What is the valuation status of GSK PLC-SPON ADR (GSK) stock?

ChartMill assigns a valuation rating of 8 / 10 to GSK PLC-SPON ADR (GSK). This can be considered as Undervalued.


How profitable is GSK PLC-SPON ADR (GSK) stock?

GSK PLC-SPON ADR (GSK) has a profitability rating of 8 / 10.


What is the financial health of GSK PLC-SPON ADR (GSK) stock?

The financial health rating of GSK PLC-SPON ADR (GSK) is 4 / 10.


What is the earnings growth outlook for GSK PLC-SPON ADR?

The Earnings per Share (EPS) of GSK PLC-SPON ADR (GSK) is expected to grow by 8.81% in the next year.